It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
23andMe is a leading consumer genetics and research company that offers a personalized health and wellness experience and has built a premier genetic database to unlock insights leading to the rapid discovery of promising new targets for drug development
Transaction will provide the capital to fund additional investment in key growth initiatives across 23andMe’s consumer health and therapeutics businesses
The transaction will value the outstanding shares of capital stock of 23andMe at an aggregate enterprise value of approximately $3.5 billion
23andMe CEO and Co-Founder Anne Wojcicki and Virgin Group’s Sir Richard Branson are each investing $25 million into the $250 million PIPE and are joined by leading institutional investors including Fidelity Management & Research Company LLC, Altimeter Capital, Casdin Capital, and Foresite Capital
The pro forma cash balance of the combined company will exceed $900 million at closing
Current shareholders of 23andMe will own 81% of the combined company
23andMe offers its customers the option to participate in genetic research. To date, more than 80% of customers have chosen to participate.
Further concerns arise as testing companies often align themselves with pharmaceutical companies, public and private research organizations, and Google. For example, “GlaxoSmithKline purchased a $300 million stake in the company, allowing the pharmaceutical giant to use 23andMe’s trove of genetic data to develop new drugs — and raising new privacy concerns for consumers.” (Ducharme, 2018) Similarly, Ancestry is sharing its data with Google through its research subsidiary Calico. Ancestry admits that “once they share people’s genetic information with partner companies, they can’t be responsible for security protocols of those partners.” (Leavenworth, 2018).
Additionally, both 23andMe and Ancestry use Google Analytics to provide third parties with consumer information for targeted marketing. In its privacy policy 23andMe states that “when you use our Services, including our website or mobile app(s), our third-party service providers may collect Web-Behavior Information about your visit, such as the links you clicked on, the duration of your visit, and the URLs you visited.” This use of shared information allows testing services and third parties to build a comprehensive personal profile on you, which may include your genetic information.
originally posted by: Zarniwoop
23andMe offers its customers the option to participate in genetic research. To date, more than 80% of customers have chosen to participate.
Is participation opt in or opt out, I wonder.
Companies like this freak me out due to the potential of what they can do with your data.
originally posted by: Bluntone22
Just wait until insurance companies start to adjust rates based on your genetic disposition.
originally posted by: NightVision
a reply to: dug88
Legalized eugenics. Hitler's vision realized.